MI-888 is a potent MDM2 inhibitor (Ki = 0.44 nM) with a superior pharmacokinetic profile and enhanced in vivo efficacy. MI-888 is capable of achieving rapid, complete, and durable tumor regression in two types of xenograft models of human cancer with oral administration and represents the most potent and efficacious MDM2 inhibitor reported to date.
Fendiline is a coronary vasodilator that inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as an antiarrhythmic and antianginal agent.